Abstract
The 90 kDa heat shock proteins (Hsp90) are proving to be an excellent target for the development of novel anticancer agents designed to selectively block the growth and proliferation of tumor cells. Since Hsp90 is a molecular chaperone and is responsible for folding numerous oncogenic proteins, its inhibition represents a novel approach toward the simultaneous disruption of multiple signaling cascades. This review summarizes recent literature implicating Hsp90 as a key facilitator for the maturation of proteins represented in all six hallmarks of cancer: 1) growth signal self-sufficiency, 2) anti-growth signal insensitivity, 3) evasion of apoptosis, 4) unlimited replicative potential, 5) metastasis and tissue invasion, and 6) sustained angiogenesis. Also described are recent advances towards the development of novel Hsp90 inhibitors via structure-based drug design that have contributed to the number of compounds undergoing clinical development.
Keywords: Hsp90, heat shock protein, cancer, inhibitor, molecular chaperone, protein folding, geldanamycin, radicicol
Current Cancer Drug Targets
Title: Hsp90: A Novel Target for the Disruption of Multiple Signaling Cascades
Volume: 7 Issue: 4
Author(s): Stephanie C. Bishop, Joseph A. Burlison and Brian S. J. Blagg
Affiliation:
Keywords: Hsp90, heat shock protein, cancer, inhibitor, molecular chaperone, protein folding, geldanamycin, radicicol
Abstract: The 90 kDa heat shock proteins (Hsp90) are proving to be an excellent target for the development of novel anticancer agents designed to selectively block the growth and proliferation of tumor cells. Since Hsp90 is a molecular chaperone and is responsible for folding numerous oncogenic proteins, its inhibition represents a novel approach toward the simultaneous disruption of multiple signaling cascades. This review summarizes recent literature implicating Hsp90 as a key facilitator for the maturation of proteins represented in all six hallmarks of cancer: 1) growth signal self-sufficiency, 2) anti-growth signal insensitivity, 3) evasion of apoptosis, 4) unlimited replicative potential, 5) metastasis and tissue invasion, and 6) sustained angiogenesis. Also described are recent advances towards the development of novel Hsp90 inhibitors via structure-based drug design that have contributed to the number of compounds undergoing clinical development.
Export Options
About this article
Cite this article as:
Bishop C. Stephanie, Burlison A. Joseph and J. Blagg S. Brian, Hsp90: A Novel Target for the Disruption of Multiple Signaling Cascades, Current Cancer Drug Targets 2007; 7 (4) . https://dx.doi.org/10.2174/156800907780809778
DOI https://dx.doi.org/10.2174/156800907780809778 |
Print ISSN 1568-0096 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5576 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Sesbania: A Prospective Candidate to be Excavated for Anticancer Drugs
The Natural Products Journal Bladder Cancer and Stem Cells
Current Signal Transduction Therapy Pharmacogenomics: A Tool to Prevent and Cure Coronary Heart Disease
Current Pharmaceutical Design Quantitative Color Doppler Ultrasonography Measurement of Thyroid Blood Flow in Patients with Graves’ Disease
Current Medical Imaging NGR-based Strategies for Targeting Delivery of Chemotherapeutics to Tumor Vasculature
Anti-Cancer Agents in Medicinal Chemistry Editorial [Hot Topic: MicroRNA Regulation and its Biological Significance in Personalized Medicine and Aging (Guest Editor: Eugenia Wang)]
Current Genomics Preface
Current Molecular Medicine Stimulation of DDX3 Expression by Ginsenoside Rg3 through the Akt/p53 Pathway Activates the Innate Immune Response via TBK1/IKKε/IRF3 Signalling
Current Medicinal Chemistry Molecular Modeling of Sulfonylmorpholinopyrimidines as the Ataxia Telangiectasis Mutated and RAD3-related (ATR) Protein Kinase Inhibitors by Computational Explorations
Letters in Drug Design & Discovery Novel Resveratrol-chalcone Derivatives: Synthesis and Biological Evaluation
Mini-Reviews in Medicinal Chemistry Recent Advances, Issues and Patents on Medical Nanorobots
Recent Patents on Engineering Dynamic Changes in Phenotypic Groups in Patients with Stable Angina Pectoris after Treatment with Xinxuekang Capsule: A Randomized Controlled Trial
Current Vascular Pharmacology Hepcidin: Biological Activity, Analytical Methods in Biological Fluids, Clinical Applications and Antagonists. A Short Review
Current Pharmaceutical Analysis Fibroblast Growth Factors/Fibroblast Growth Factor Receptors as Targets for the Development of Anti-Angiogenesis Strategies
Current Pharmaceutical Design A Comprehensive Review on miR-200c, A Promising Cancer Biomarker with Therapeutic Potential
Current Drug Targets Targeting Cyclooxygenase and Nitric Oxide Pathway Cross-Talk: A New Signal Transduction Pathway for Developing More Effective Anti- Inflammatory Drugs
Current Signal Transduction Therapy Chemical Modifications of Synthetic RNAi Agents and in vivo Delivery Techniques
Current Bioactive Compounds Allo-Network Drugs: Extension of the Allosteric Drug Concept to Protein- Protein Interaction and Signaling Networks
Current Topics in Medicinal Chemistry Current State and Future Perspectives in QSAR Models to Predict Blood- Brain Barrier Penetration in Central Nervous System Drug R&D
Mini-Reviews in Medicinal Chemistry The Past, Present and Future Subclassification of Patients with Acute Myeloid Leukemia
Current Pharmaceutical Biotechnology